Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist

Journal of Immunology

Volumn 173, Issue 3, 2004, Pages 1681-1688

  Mortier, Erwan ^a   Bernard, Jérôme ^a   Plet, Ariane ^a   Jacques, Yannick ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ILOMASTAT; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; IONOMYCIN; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL CELL; ARTICLE; BETA CHAIN; CELL MEMBRANE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DELETION MUTANT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN SECRETION; RADIOIMMUNOASSAY; RECEPTOR AFFINITY; RECEPTOR BINDING; T LYMPHOCYTE;

EID: 3242776039     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.3.1681     Document Type: Article

References (45)

1. Fernandez-Botran, R., P. M. Chilton, and Y. Ma. 1996. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv. Immunol. 63:269.
2. Jones, S. A., and S. Rose-John. 2002. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim. Biophys. Acts. 1592:251.
3. Mullberg, J., F. H. Durie, C. Otten-Evans, M. R. Alderson, S. Rose-John, D. Cosman, R. A. Black, and K. M. Mohler. 1995. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 155:5198.
4. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, et al. 1994. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264:965.
5. Giri, J. G., D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukocyte Biol. 57:763.
6. Giri, J. G., S. Kumaki, M. Ahdieh, D. J. Friend, A. Loomis, K. Shanebeck, R. DuBose, D. Cosman, L. S. Park, and D. M. Anderson. 1995. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14:3654.
7. Norman, D. G., P. N. Barlow, M. Baron, A. J. Day, R. B. Sim, and I. D. Campbell. 1991. Three-dimensional structure of a complement control protein module in solution. J. Mol. Biol. 219:717.
8. Miyazaki, T., Z. J. Liu, A. Kawahara, Y. Minami, K. Yamada, Y. Tsujimoto, E. L. Barsoumian, R. M. Permutter, and T. Taniguchi. 1995. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81:223.
9. Johnston, J. A., C. M. Bacon, D. S. Finbloom, R. C. Rees, D. Kaplan, K. Shibuya, J. R. Ortaldo, S. Gupta, Y. Q. Chen, J. D. Giri, et al. 1995. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. USA 92:8705.
10. Nelson, B. H., and D. M. Willerford. 1998. Biology of the interleukin-2 receptor. Adv. Immunol. 70:1.
11. Jacques, Y., B. Le Mauff, F. Boeffard, A. Godard, and J. P. Soulillou. 1987. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J. Immunol. 139:2308.
12. Schulz, O., H. F. Sewell, and F. Shakib. 1998. Proteolytic cleavage of CD25, the α subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J. Exp. Med. 187:271.
13. Sheu, B. C., S. M. Hsu, H. N. Ho, H. C. Lien, S. C. Huang, and R. H. Lin. 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61:237.
14. Dummer, R., G. Posseckert, K. Sugamura, H. Grundmann, and G. Burg. 1996. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor α, β, and γ chains. J. Interferon Cytokine Res. 16:315.
15. Barelli, H., A. Petit, E. Hirsch, S. Wilk, G. De Nanteuil, P. Morain, and F. Checler. 1999. S17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem. Biophys. Res. Commun. 257:657.
16. Hori, T., T. Uchiyama, M. Tsudo, H. Umadome, H. Ohno, S. Fukuhara, K. Kita, and H. Uchino. 1987. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 70:1069.
17. Kitamura, T., T. Tange, T. Terasawa, S. Chiba, T. Kuwaki, K. Miyagawa, Y. F. Piao, K. Miyazono, A. Urabe, and F. Takaku. 1989. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140:323.
18. + TF-1 β cell line profile in response to long-term exposure to IL-15. Cytokine 9:316.
19. Nakamura, Y., S. M. Russell, S. A. Mess, M. Friedmann, M. Erdos, C. Francois, Y. Jacques, S. Adelstein, and W. J. Leonard. 1994. Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling. Nature 369:330.
20. Dubois, S., F. Magrangeas, P. Lehours, S. Raher, J. Bernard, O. Boisteau, S. Leroy, S. Minvielle, A. Godard, and Y. Jacques. 1999. Natural splicing of exon 2 of human interleukin-15 receptor α-chain mRNA results in a shortened form with a distinct pattern of expression. J. Biol. Chem. 274:26978.
21. Bernard, J., C. Harb, E. Mortier, A. Quemener, R. H. Meloen, C. Vermot-Desroches, J. Wijdeness, P. Van Dijken, J. Grotzinger, J. W. Slootstra, et al. 2004. Identification of an interleukin-15 α receptor binding site on human interleukin-15. J. Biol. Chem. 279:24313.
22. Fraker, P. J., and J. C. Speck, Jr. 1978. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a- diphrenylglycoluril. Biochem. Biophys. Res. Commun. 80:849.
23. Tejedor, F., and J. P. Ballesta. 1982. Iodination of biological samples without loss of functional activity. Anal. Biochem. 127:143.
24. Mullberg, J., H. Schooltink, T. Stoyan, M. Gunther, L. Graeve, G. Buse, A. Mackiewicz, P. C. Heinrich, and S. Rose-John. 1993. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23:473.
25. Bosco, M. C., I. Espinoza-Delgado, T. K. Rowe, M. G. Malabarba, D. L. Longo, and L. Varesio. 1997. Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. J. Immunol. 159:2922.
26. Anderson, D. M., S. Kumaki, M. Ahdieh, J. Bertles, M. Tometsko, A. Loomis, J. Giri, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, et al. 1995. Functional characterization of the human interleukin-15 receptor α chain and close linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270:29862.
27. Meazza, R., S. Basso, A. Gaggero, D. Detotero, L. Trentin, R. Pereno, B. Azzarone, and S. Ferrini. 1998. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor β/γ. Int. J. Cancer 78:189.
28. Galardy, R. E., D. Grobelny, H. G. Foellmer, and L. A. Fernandez. 1994. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res. 54:4715.
29. Bulanova, E., V. Budagian, Z. Orinska, H. Krause, R. Paus, and S. Bulfone-Paus. 2003. Mast cells express novel functional IL-15 receptor α isoforms. J. Immunol. 170:5045.
30. Hooper, N. M., E. H. Karran, and A. J. Turner. 1997. Membrane protein secretases. Biochem. J. 321:265.
31. Arribas, J., L. Coodly, P. Vollmer, T. K. Kishimoto, S. Rose-John, and J. Massague. 1996. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 271:11376.
32. Mullberg, J., H. Schooltink, T. Stoyan, P. C. Heinrich, and S. Rose-John. 1992. Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem. Biophys. Res. Commun. 189:794.
33. + mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur. J. Immunol. 28:3514.
34. Esteve, P. O., E. Chicoine, O. Robledo, F. Aoudjit, A. Descoteaux, E. F. Potworowski, and Y. St-Pierre. 2002. Protein kinase C-ζ regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-α in glioma cells via NF-κB. J. Biol. Chem. 277:35150.
35. Fernandez-Botran, R., and E. S. Vitetta. 1990. A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA 87:4202.
36. Fernandez-Botran, R., and E. S. Vitetta. 1991. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 174:673.
37. Heaney, M. L., and D. W. Golde. 1998. Soluble receptors in human disease. J. Leukocyte Biol. 64:135.
38. Fehniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15: biology and relevance to human disease. Blood 97:14.
39. McInnes, I. B., J. al-Mughales, M. Field, B. P. Leung, F. P. Huang, R. Dixon, R. D. Sturrock, P. C. Wilkinson, and F. Y. Liew. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2:175.
40. Liu, Z., K. Geboes, S. Colpaert, G. R. D'Haens, P. Rutgeerts, and J. L. Ceuppens. 2000. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J. Immunol. 164:3608.
41. Agostini, C., L. Trentin, M. Facco, R. Sancetta, A. Cerutti, C. Tassinari, L. Cimarosto, F. Adami, A. Cipriani, R. Zambello, and G. Semenzato. 1996. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J. Immunol. 157:910.
42. Kakumu, S., A. Okumura, T. Ishikawa, M. Yano, A. Enomoto, H. Nishimura, K. Yoshioka, and Y. Yoshika. 1997. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-α (TNF-α) receptors in type C chronic liver disease. Clin. Exp. Immunol. 109:458.
43. Moreland, L. W., S. W. Baumgartner, M. H. Schiff, E. A. Tindall, R. M. Fleischmann, A. L. Weaver, R. E. Ettlinger, S. Cohen, W. J. Koopman, K. Mohler, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141.
44. Smith, X. G., E. M. Bolton, H. Ruchatz, X. Wei, F. Y. Liew, and J. A. Bradley. 2000. Selective blockade of IL-15 by soluble IL-15 receptor α-chain enhances cardiac allograft survival. J. Immunol. 165:3444.
45. Ruchatz, H., B. P. Leung, X. Q. Wei, I. B. McInnes, and F. Y. Liew. 1998. Soluble IL-15 receptor α-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160:5654.